Merus N.V. (MRUS), a clinical-stage oncology company, will be presenting updated data on its phase II trial of Petosemtamab monotherapy in previously treated, 2L+, recurrent/metastatic head and neck squamous cell carcinoma at the ESMO Asia Congress tomorrow (Dec.7, 2024).
According to the interim clinical update reported at the AACR Annual Meeting last year, Petosemtamab monotherapy in 2L+ HNSCC demonstrated a 37% response rate among 43 evaluable patients.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.